Anxiolytic effect of pterostilbene
View Patent ↗We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses. Western blot analysis corroborated the observed behaviors in the EPM, revealing a decrease in both ERK1 and ERK2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg doses; the 5 and 10 mg/kg doses showed no significant effect on the phosphorylation of ERKs. Pterostilbene was detected in serum and brain tissue following a single oral administration, demonstrating that the compound can cross the blood-brain barrier to reach the brain regions, including hippocampus, and thereby exert its anxiolytic effect. Resveratrol, the parent molecule of pterostilbene, did not have any anxiolytic effect.
1. A method for treating an anxiety disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical or nutraceutical composition comprising a therapeutically effective amount of pterostilbene wherein a therapeutic anxiolytic effect results after a single administration of said therapeutically effective amount of pterostilbene and said therapeutic anxiolytic effect is comparable to the therapeutic anxiolytic effect of Diazepam, a positive anxiolytic control, and is substantially free of sedative side effects.
2. The method of claim 1 wherein said therapeutic anxiolytic effect resulting from the administration of said therapeutically effective amount of pterostilbene manifests as a dose-dependent response as compared to a negative control.
3. The method of claim 1 wherein said administration of said therapeutically effective amount of pterostilbene results in a marked reduction of ERK1 levels in the hippocampus and said reduction of ERK1 activity correlates with a therapeutic anxiolytic effect.
4. The method of claim 1 wherein said subject is a mammal suffering from an anxiety disorder.
5. The method of claim 1 wherein said subject is a human suffering from an anxiety disorder.
6. The method of claim 1 wherein said amount is a total amount and said total amount is based on the body weight and the body surface area of said mammal.
7. The method of claim 6 wherein said amount is a total amount of about 10 mg /day to about 100 mg/day.
8. The method of claim 1 wherein said nutraceutical composition is a food or beverage or a supplement composition for a food or beverage.
9. The method of claim 8 wherein said amount is present in an amount of about 10 mg/day to about 100 mg/day.